India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has granted AstraZeneca permission to market its HER2-targeting cancer therapy Enhertu (trastuzumab deruxtecan) for a new, expanded breast cancer indication, as reported by Business Standard, NDTV Profit and Medical Dialogues in early August 2026. The approval extends the drug’s reach in India beyond the first-line HER2-positive breast cancer indication cleared earlier in June 2026, and reinforces a broader trend of advanced oncology therapies becoming available to Indian patients. For international buyers and distributors tracking India’s pharmaceutical landscape, this approval signals both growing regulatory momentum in oncology approvals and the widening cost gap between branded biological cancer drugs and their biosimilar and generic alternatives.<\/p>\n\n\n\n
On 8 August 2026, multiple Indian media outlets including Business Standard, NDTV Profit and Medical Dialogues reported that AstraZeneca Pharma India received CDSCO approval to market Enhertu for an additional breast cancer indication. The approval follows a 28 July 2026 CDSCO nod, reported by Indian Pharma Post and CNBC TV18, to import and distribute the drug in India for HER2-positive breast cancer \u2014 with Sahi and Indian Pharma Post characterising the expanded use as covering Stage II\/III breast cancer. This latest clearance adds to Enhertu’s regulatory footprint in the country rather than replacing it.<\/p>\n\n\n\n
The sequence of successive approvals reflects India’s evolving approach to clearing modern targeted cancer therapies while managing cost and access concerns. As reported by The Economic Times in June 2026 and Express Pharma, CDSCO had previously cleared Enhertu for first-line HER2-positive breast cancer \u2014 the expanded-use decisions in July and August 2026 broaden the patient population eligible to receive the therapy.<\/p>\n\n\n\n\n\n
Enhertu is the brand name for trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo. The medicine combines a HER2-targeting antibody with a cytotoxic chemotherapy payload, allowing the drug to deliver treatment directly to HER2-positive tumour cells while limiting damage to healthy tissue [CITATION NEEDED for exact payload mechanism]. It is given by intravenous infusion, and in breast cancer the standard dosing schedule is typically 5.4 mg\/kg every three weeks [CITATION NEEDED].<\/p>\n\n\n\n
Because Enhertu is a complex biological product, it is not a small-molecule generic medicine like most drugs manufactured in bulk in India. It belongs to the category of advanced biologics for which biosimilar development and regulatory pathways are still maturing in India. This distinction matters for buyers: the reference biologic remains expensive, and affordable alternatives depend on the progress of Indian biosimilar developers and on the CDSCO’s biosimilar approval framework.<\/p>\n\n\n\n\n\n
The expanded breast cancer approval is not Enhertu’s first in India. According to Medical Dialogues and BioSpectrum India, in October 2025 CDSCO permitted the drug’s use in HER2-positive solid tumours and tumour-agnostic settings, where the therapy can be used based on the presence of HER2 expression rather than the tumour’s location. This was followed by the June 2026 clearance for first-line HER2-positive breast cancer, reported by The Economic Times, CNBC TV18 and Express Pharma.<\/p>\n\n\n\n
The pattern of successive, stepwise CDSCO approvals is consistent with the regulator’s recent emphasis on accelerating drug approvals. As covered elsewhere on indiamedicine.org, CDSCO has introduced faster testing-clearance norms and has committed to a digital drug regulatory platform to streamline the approval pipeline. For the oncology community, each Enhertu approval broadens eligibility and gives oncologists more flexibility in treating HER2-positive breast cancer.<\/p>\n\n\n\n\n\n
CDSCO approval is the first regulatory step \u2014 but approval does not guarantee affordability. Enhertu, as an originator antibody-drug conjugate, carries a substantial price tag in most markets, and Indian patients and hospitals face a significant cost barrier when branded biological oncology therapies are launched. The commercial success of the drug in India will depend on pricing, patient-access programmes, and ultimately the arrival of biosimilar versions once exclusivity allows [CITATION NEEDED for India-specific pricing figures].<\/p>\n\n\n\n
For the broader Indian generic and biosimilar sector, this approval underscores a familiar dynamic: originator biologics capture the market first at high prices, and affordable access follows only when Indian manufacturers secure approvals for biosimilars or when the reference product faces competition. Buyers monitoring India’s oncology market should track both the reference biologic’s rollout and the pipeline of Indian biosimilar candidates for trastuzumab-based therapies.<\/p>\n\n\n\n\n\n